Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02680535 · ClinicalTrials.gov registry record · NA
MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue
A NA study of Neoplasms of the Prostate, sponsored by Nanospectra Biosciences.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT02680535 is a NA study of Neoplasms of the Prostate that has completed, run by Nanospectra Biosciences. The registered enrollment target is 45 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT02680535, a NA study of Neoplasms of the Prostate, has completed, sponsored by Nanospectra Biosciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
To determine the efficacy of using MRI/US fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser irradiation.
Conditions Studied
Interventions
- DEVICE AuroShell particle infusion
Study Locations (5)
Texas
- The University of Texas Medical Branch - Galveston
- University of Texas Medical School at Houston - Houston
Maryland
- Johns Hopkins Hospital - Baltimore
Michigan
- University of Michigan - Ann Arbor
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2016-02 |
| Est. Completion | 2020-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02680535
The ClinicalTrials.gov registry entry for NCT02680535 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nanospectra Biosciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms of the Prostate appearing as the primary indexed condition, and to 1 intervention - of which AuroShell particle infusion is the first listed.
NCT02680535 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT02680535 about?
NCT02680535 is a clinical study titled "MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue". To determine the efficacy of using MRI/US fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser irradiation.
What is the current status of trial NCT02680535?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2016-02. Estimated completion is 2020-10.
What conditions does trial NCT02680535 study?
This clinical trial studies the following conditions: Neoplasms of the Prostate.
What interventions are being tested in trial NCT02680535?
The interventions under investigation include: AuroShell particle infusion (DEVICE).
Who is sponsoring clinical trial NCT02680535?
This trial is sponsored by Nanospectra Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02680535 being conducted?
This trial has 5 study locations across Maryland, Michigan, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.